Included among the purchasers of the shares is Peter Friedli, the company’s chairman, individually. The board of directors of the company, including all of the company’s independent directors, but with Mr Friedli abstaining, unanimously approved the offering and sale of the shares, including the sale of a portion of the shares to Mr Friedli.
Sudhir Sahasrabudhe, chief scientific officer of Prolexys, said: “Raising the new capital under such favorable terms was an excellent opportunity for Prolexys to further advance the clinical development of PRLX 93936, a novel small molecule with potent and selective anti-tumor activity in the disease models representative of colon, lung, pancreatic, and ovarian cancer, several sarcoma sub-types and multiple myeloma.
“This new investment by Mr Friedli underscores his confidence and long-term commitment to support the development of novel cancer therapeutics at Prolexys. We are grateful for his continued guidance and support.”